Literature DB >> 21877198

The CDK inhibitors in cancer research and therapy.

Jonas Cicenas1, Mindaugas Valius.   

Abstract

Chemical compounds that interfere with an enzymatic function of kinases are useful for gaining insight into the complicated biochemical processes in mammalian cells. Cyclin-dependent kinases (CDK) play an essential role in the control of the cell cycle and/or proliferation. These kinases as well as their regulators are frequently deregulated in different human tumors. Aberrations in CDK activity have also been observed in viral infections, Alzheimer's, Parkinson's diseases, ischemia and some proliferative disorders. This led to an intensive search for small-molecule CDK inhibitors not only for research purposes, but also for therapeutic applications. Here, we discuss seventeen CDK inhibitors and their use in cancer research or therapy. This review should help researchers to decide which inhibitor is best suited for the specific purpose of their research. For this purpose, the targets, commercial availability and IC(50) values are provided for each inhibitor. The review will also provide an overview of the clinical studies performed with some of these inhibitors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21877198     DOI: 10.1007/s00432-011-1039-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  81 in total

1.  CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.

Authors:  Donna E Hansel; Surajit Dhara; RuChih C Huang; Raheela Ashfaq; Mari Deasel; Yutaka Shimada; Harold S Bernstein; John Harmon; Malcolm Brock; Arlene Forastiere; M Kay Washington; Anirban Maitra; Elizabeth Montgomery
Journal:  Am J Surg Pathol       Date:  2005-03       Impact factor: 6.394

Review 2.  Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.

Authors:  Peter M Fischer; Athos Gianella-Borradori
Journal:  Expert Opin Investig Drugs       Date:  2005-04       Impact factor: 6.206

3.  ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis.

Authors:  Sofie Svensson; Karin Jirström; Lisa Rydén; Göran Roos; Stefan Emdin; Michael C Ostrowski; Göran Landberg
Journal:  Oncogene       Date:  2005-06-23       Impact factor: 9.867

4.  A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study.

Authors:  Edward C Grendys; John A Blessing; Robert Burger; James Hoffman
Journal:  Gynecol Oncol       Date:  2005-08       Impact factor: 5.482

5.  Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

Authors:  G K Schwartz; D Ilson; L Saltz; E O'Reilly; W Tong; P Maslak; J Werner; P Perkins; M Stoltz; D Kelsen
Journal:  J Clin Oncol       Date:  2001-04-01       Impact factor: 44.544

6.  Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  C Tom Kouroukis; Andrew Belch; Michael Crump; Elizabeth Eisenhauer; Randy D Gascoyne; Ralph Meyer; Reinhard Lohmann; Pedro Lopez; Jean Powers; Robert Turner; Joseph M Connors
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

7.  Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

Authors:  Mitch A Phelps; Thomas S Lin; Amy J Johnson; Eunju Hurh; Darlene M Rozewski; Katherine L Farley; Di Wu; Kristie A Blum; Beth Fischer; Sarah M Mitchell; Mollie E Moran; Michelle Brooker-McEldowney; Nyla A Heerema; David Jarjoura; Larry J Schaaf; John C Byrd; Michael R Grever; James T Dalton
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

8.  A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer.

Authors:  Richard D Carvajal; Archie Tse; Manish A Shah; Robert A Lefkowitz; Mithat Gonen; Lisa Gilman-Rosen; Jeremy Kortmansky; David P Kelsen; Gary K Schwartz; Eileen M O'Reilly
Journal:  Pancreatology       Date:  2009-05-19       Impact factor: 3.996

9.  Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection.

Authors:  Pascal Loyer; Janeen H Trembley; Jose A Grenet; Adeline Busson; Anne Corlu; Wei Zhao; Mehmet Kocak; Vincent J Kidd; Jill M Lahti
Journal:  J Biol Chem       Date:  2008-01-23       Impact factor: 5.157

10.  Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.

Authors:  Antoinette R Tan; Donna Headlee; Richard Messmann; Edward A Sausville; Susan G Arbuck; Anthony J Murgo; Giovanni Melillo; Suoping Zhai; William D Figg; Sandra M Swain; Adrian M Senderowicz
Journal:  J Clin Oncol       Date:  2002-10-01       Impact factor: 44.544

View more
  71 in total

Review 1.  The Role of CDK4/6 Inhibition in Breast Cancer.

Authors:  Conleth G Murphy; Maura N Dickler
Journal:  Oncologist       Date:  2015-04-15

2.  Biased Docking for Protein-Ligand Pose Prediction.

Authors:  Juan Pablo Arcon; Adrián G Turjanski; Marcelo A Martí; Stefano Forli
Journal:  Methods Mol Biol       Date:  2021

3.  Computational analysis of kinase inhibitor selectivity using structural knowledge.

Authors:  Yu-Chen Lo; Tianyun Liu; Kari M Morrissey; Satoko Kakiuchi-Kiyota; Adam R Johnson; Fabio Broccatelli; Yu Zhong; Amita Joshi; Russ B Altman
Journal:  Bioinformatics       Date:  2019-01-15       Impact factor: 6.937

Review 4.  Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1.

Authors:  Nandini Sakurikar; Alan Eastman
Journal:  Cell Cycle       Date:  2016-03-17       Impact factor: 4.534

5.  Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells.

Authors:  Olivia Morris-Hanon; Mariela Claudia Marazita; Leonardo Romorini; Luciana Isaja; Damián Darío Fernandez-Espinosa; Gustavo Emilio Sevlever; María Elida Scassa; Guillermo Agustín Videla-Richardson
Journal:  Mol Neurobiol       Date:  2019-05-23       Impact factor: 5.590

6.  Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies.

Authors:  Rajul K Jain; David S Hong; Aung Naing; Jennifer Wheler; Thorunn Helgason; Nai-Yi Shi; Yash Gad; Razelle Kurzrock
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 7.  Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal.

Authors:  Chandra Sekhar Kuruva; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2016-10-27       Impact factor: 7.851

8.  Interferon regulatory factor 4 sustains CD8(+) T cell expansion and effector differentiation.

Authors:  Shuyu Yao; Bruno Fernando Buzo; Duy Pham; Li Jiang; Elizabeth J Taparowsky; Mark H Kaplan; Jie Sun
Journal:  Immunity       Date:  2013-11-07       Impact factor: 31.745

9.  Discovery of novel 5-fluoro-N2,N4-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9.

Authors:  Jiadi Gao; Cheng Fang; Zhiyan Xiao; Li Huang; Chin-Ho Chen; Li-Ting Wang; Kuo-Hsiung Lee
Journal:  Medchemcomm       Date:  2015-03-01       Impact factor: 3.597

10.  Cell cycle-related kinase in carcinogenesis.

Authors:  Ye Tian; Han Wan; Guang Tan
Journal:  Oncol Lett       Date:  2012-07-27       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.